FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with advanced ovarian cancer.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
